Abstract
Background:
Diabetes mellitus remarkably increases the possibility of cardiovascular disease, the major cause of death in diabetic patients. Traditional treatment settlement may fail to find out the various pathophysiological mechanisms fundamental role in these complications.
Objective:
This study aims to assess the effectiveness of novel therapeutic strategies which includes GLP-1 receptor agonists, SGLT2 inhibitors, and anti-inflammatory factor when linked with precision medicine and individualized treatment structure in management diabetes-related cardio-vascular difficulties.
Methods:
A multi-center, irregular controlled trial which involves 440 patients with type 2 diabetes and already present CVD was held over 18 months. Participants were separated into standard care and precision-guided therapy groups. Results measures included changes in HbA1c, lipid profiles, cardio-vascular events, and quality of life.
Results:
Precision-guided therapy leads to a remarkable improvements in cardio-vascular results, glycemic control, and patient-reported quality of life metrics. SGLT2 inhibitors and GLP-1 receptor agonists, in contrast with genetic and biomarker-driven individualized, showing identified effectiveness over standard treatment agreement.
Conclusion:
Combining the novel therapies with precision medicine terminologies presents a transformative link in management of cardio-vascular complications in diabetic patients, who promise to improve results and personalized care pathways.
Keywords: Glycemic, cardiovascular, efficacy, Hb